BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Heplisav: Phase III ongoing

Dynavax said an independent DSMB recommended continuation of a pair of Phase III trials of Heplisav after reviewing safety data from 2,264 patients who received a single injection, including 1,611 patients who have received 2 injections. In September, the company said FDA...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >